Jacob C, Tollenaere M, Kachar H, Potier M, De Deyn P, Van Dam D
Heliyon. 2025; 11(1):e41445.
PMID: 39850411
PMC: 11755057.
DOI: 10.1016/j.heliyon.2024.e41445.
Sukreet S, Rafii M, Rissman R
Alzheimers Dement (Amst). 2024; 16(2):e12580.
PMID: 38623383
PMC: 11016820.
DOI: 10.1002/dad2.12580.
Rose D, Bentley L, Maity A, Maguire R, Planchart A, Spasojevic I
Heliyon. 2024; 10(3):e25578.
PMID: 38356491
PMC: 10865309.
DOI: 10.1016/j.heliyon.2024.e25578.
Perluigi M, Tramutola A, Pagnotta S, Barone E, Butterfield D
Antioxidants (Basel). 2020; 9(9).
PMID: 32839417
PMC: 7554729.
DOI: 10.3390/antiox9090779.
Silvestro S, Calcaterra V, Pelizzo G, Bramanti P, Mazzon E
Antioxidants (Basel). 2020; 9(5).
PMID: 32408702
PMC: 7278841.
DOI: 10.3390/antiox9050414.
The Role of Oxidative Stress in the Pathomechanism of Congenital Malformations.
Laforgia N, Di Mauro A, Favia Guarnieri G, Varvara D, De Cosmo L, Panza R
Oxid Med Cell Longev. 2019; 2018:7404082.
PMID: 30693064
PMC: 6332879.
DOI: 10.1155/2018/7404082.
HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.
Barone E, Head E, Butterfield D, Perluigi M
Free Radic Biol Med. 2016; 111:262-269.
PMID: 27838436
PMC: 5639937.
DOI: 10.1016/j.freeradbiomed.2016.10.508.
Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial.
Sano M, Aisen P, Andrews H, Tsai W, Lai F, Dalton A
Neurology. 2016; 86(22):2071-6.
PMID: 27164691
PMC: 4891209.
DOI: 10.1212/WNL.0000000000002714.
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
Head E, Lott I, Wilcock D, Lemere C
Curr Alzheimer Res. 2015; 13(1):18-29.
PMID: 26651341
PMC: 4948181.
DOI: 10.2174/1567205012666151020114607.
Identification of a DNA methylation signature in blood cells from persons with Down Syndrome.
Bacalini M, Gentilini D, Boattini A, Giampieri E, Pirazzini C, Giuliani C
Aging (Albany NY). 2015; 7(2):82-96.
PMID: 25701644
PMC: 4359691.
DOI: 10.18632/aging.100715.
Alzheimer's Disease in Down Syndrome.
Head E, Powell D, Gold B, Schmitt F
Eur J Neurodegener Dis. 2014; 1(3):353-364.
PMID: 25285303
PMC: 4184282.
Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.
Zis P, McHugh P, McQuillin A, Pratico D, Dickinson M, Shende S
PLoS One. 2014; 9(6):e97709.
PMID: 24901945
PMC: 4046955.
DOI: 10.1371/journal.pone.0097709.
Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.
Perluigi M, Di Domenico F, Buttterfield D
Proteomics Clin Appl. 2013; 8(1-2):73-85.
PMID: 24259517
PMC: 3965623.
DOI: 10.1002/prca.201300066.
Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.
Tolun A, Scarbrough P, Zhang H, McKillop J, Wang F, Kishnani P
Ann Epidemiol. 2012; 22(12):892-4.
PMID: 23063134
PMC: 3508197.
DOI: 10.1016/j.annepidem.2012.09.005.
Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.
Perluigi M, Butterfield D
Curr Gerontol Geriatr Res. 2011; 2012:724904.
PMID: 22203843
PMC: 3235450.
DOI: 10.1155/2012/724904.
4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.
Perluigi M, Coccia R, Butterfield D
Antioxid Redox Signal. 2011; 17(11):1590-609.
PMID: 22114878
PMC: 3449441.
DOI: 10.1089/ars.2011.4406.
Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.
Cenini G, Dowling A, Beckett T, Barone E, Mancuso C, Murphy M
Biochim Biophys Acta. 2011; 1822(2):130-8.
PMID: 22009041
PMC: 3260028.
DOI: 10.1016/j.bbadis.2011.10.001.
Heat shock proteins as biomarkers for the rapid detection of brain and spinal cord ischemia: a review and comparison to other methods of detection in thoracic aneurysm repair.
Hecker J, McGarvey M
Cell Stress Chaperones. 2010; 16(2):119-31.
PMID: 20803353
PMC: 3059797.
DOI: 10.1007/s12192-010-0224-8.
Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease.
Mufson E, Leurgans S
Neurodegener Dis. 2010; 7(1-3):139-42.
PMID: 20197693
PMC: 3221250.
DOI: 10.1159/000289224.
Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry.
Zhang H, Ilyasova D, Sztaray J, Young S, Wang F, Millington D
Anal Biochem. 2009; 399(2):302-4.
PMID: 20026293
PMC: 2853187.
DOI: 10.1016/j.ab.2009.12.024.